Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment

• Published in: International journal of mycobacteriology Vol. 5; no. 4; pp. 482 - 488
• Main Authors: Ngouleun, Williams, Biapa Nya, Prosper Cabral, Pieme, Anatole Constant, Telefo, Phelix Bruno
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.12.2016; Medknow Publications and Media Pvt. Ltd; Wolters Kluwer Medknow Publications
• Subjects: Adolescent; Adult; Aged; AIDS; ALT; Antitubercular Agents - adverse effects; Antitubercular Agents - therapeutic use; AST; Cameroon; Chemical and Drug Induced Liver Injury - epidemiology; Coinfection; Coinfection - complications; Coinfection - drug therapy; Comorbidity; Diagnosis; Drug therapy; Female; Hepatotoxicity; HIV Infections - complications; Humans; Infectious Disease; Male; Medical Education; Middle Aged; Prospective Studies; Retrospective Studies; Rifampin; Risk Assessment; Tuberculosis; Tuberculosis - complications; Tuberculosis - drug therapy; Young Adult; Cameroon; AIDS; ALT; AST; Coinfection; Tuberculosis; Hepatotoxicity
• ISSN: 2212-5531; 2212-554X
• DOI: 10.1016/j.ijmyco.2016.05.003

Abstract Objective/background Tuberculosis (TB) is a worldwide public health problem. It is a contagious and grave disease caused by Mycobacterium tuberculosis . Current drugs such as isoniazid, pyrazinamide, and rifampicin used for the treatment of tuberculosis are potentially hepatotoxic and can lead to drug hepatitis. In order to improve the follow-up of TB patients in Cameroon, we carried out a study which aimed to evaluate the hepatotoxicity risk factors associated with anti-TB drugs. Methods The studies were performed on 75 participants who had visited the Loum District Hospital located in the littoral region of Cameroon for their routine consultation. Participants have been selected based on pre-established criteria of inclusion and exclusion. Prior to the informed consent signature, patients were given compelling information about the objective and the result output of the study. They were questioned about antioxidant food and alcohol consumption as well as some clinical signs of hepatotoxicity such as fever, nausea, vomiting, and tiredness. The collected blood was tested for the determination of biochemical markers (transaminases and C-reactive protein) using standard spectrophotometric methods. Results Biochemical analysis of samples showed a significant increase ( p < .05) of aspartate aminotransferase and alanine aminotransferase values in TB patients coinfected with human immunodeficiency virus/AIDS (33.28 ± 16.58 UI/L and 30.84 ± 17.17 UI/L, respectively) compared with the respective values of the controls (16.35 ± 5.31 UI/L and 16.45 ± 4.83 UI/L). Taking individually, the liver injury patient percentage of TB patients was significant compared to TBC when considering alanine aminotransferase and aspartate aminotransferase parameters. When considering risk factors, antioxidant food consumption significantly reduced the liver injury patient percentage for the above parameters, whereas an opposite situation was observed with alcohol consumption between TB-coinfection and TB patients. Regarding the C-reactive protein results, the percentage of positive tests was very high among coinfected patients (40%) compared with the control (15%). The interactions between parameters related to alcohol consumption and intake of antioxidant foods showed a slight decrease in activity compared with interactions without food. Conclusion The results showed that human immunodeficiency virus status and alcohol consumption constitutes aggravating factors for the occurrence of hepatic toxicity. In addition, the consumption of antioxidant foods simultaneously with TB drugs help in reducing the hepatotoxic effects of these drugs.